Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Elektrofi

Elektrofi IPO

$402.83MM
Series C Valuation, Aug 2024
Register for details
For more details on financing and valuation of private companies similar to Elektrofi before its M&A, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Elektrofi IPO date and status

2015
Founded
Nov 2025
MA Closed

Company details

Elektrofi develops innovative drug delivery technologies, particularly focusing on improving the stability and efficacy of injectable medications using their proprietary electrostatic stabilization method.
Founded
2015
Headquarters
Boston, MA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$402.83MM
Total Funding
$284.44MM
Last Funding Round
Series C

Learn more about Elektrofi

To invest in Elektrofi pre-IPO

Can you invest in Elektrofi pre-IPO?

You can no longer invest in Elektrofi with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Elektrofi before it goes public?

You can no longer sell shares of Elektrofi on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Elektrofi shares?

Forge can no longer determine the value of Elektrofi shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Elektrofi a publicly traded company?

Elektrofi became a public company following its M&A on 11/18/2025 and is now a publicly traded company.

To learn more about Elektrofi potential IPO

Will Elektrofi go IPO?

Elektrofi became a public company following its M&A on 11/18/2025.

What is Elektrofi’s IPO price?

The IPO price of Elektrofi is not currently available.

When was Elektrofi founded?

Elektrofi was founded in 2015.

What is Elektrofi funding to date?

Elektrofi has raised $284.44MM to date.

Elektrofi pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
08/08/2024 Series C $96.45MM $14.04 $402.83MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
6,869,899
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/13/2022 Series B $42.55MM $5.87 $131.18MM Bvf Partners, Janus Henderson Investors, Logos Capital, Marshall Wace
Price per Share
$ xx.xx
Shares Outstanding
7,247,448
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bvf Partners, Janus Henderson Investors, Logos Capital, Marshall Wace
06/30/2018 Series A-1 $1.13MM $1.15 $10.79MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
980,681
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
06/30/2018 Series A $2.09MM $1.14 $10.79MM Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
1,826,348
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Elektrofi IPO news and media highlights

Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line

Novartis entered an exclusive licensing deal with Lindy Biosciences to develop subcutaneous versions of Novartis' biologic drugs using Lindy's Microglassification technology. The deal provides Novartis global rights to the technology for multiple targets and includes up to $934 million in potential milestone payments to Lindy plus royalties on sales.

Protein Microparticles Turn Infusions into Injectables

Elektrofi is developing technology to reformulate large-molecule therapeutics into highly concentrated solutions for subcutaneous injection, enabling convenient at-home administration and reducing the need for infusions. The company has partnerships with pharmaceutical companies and plans to start clinical trials in 2025.

Elektrofi bags $40m funding to establish manufacturing line

Elektrofi, a biotech focused on drug formulation, raised $40 million in a Series B financing round. The funding will help establish a manufacturing line to support upcoming clinical trials, expand its pipeline, and double its headcount. The company aims to address unmet needs for stabilized and concentrated biologics using its microparticle technology platform.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
VeraDermicsVeraDermicsNot available$ xx.xxSeries C$306.13MM$1.27$151MM
Eikon TherapeuticsEikon TherapeuticsNot available$ xx.xxSeries D$1.57B$5.84$326.93MM
Spyglass PharmaSpyglass PharmaNot available$ xx.xxSeries D$350.04MM$2.33$75MM
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
SpaceX SpaceX $550.00 +$102.77 (22.98%)High $xxx.xx
Anduril Anduril $105.00 -$0.53 (0.50%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
OpenAI OpenAI $723.12 +$0.12 (0.02%)High $xxx.xx
Anduril Anduril $105.00 -$0.53 (0.50%)High $xxx.xx
Databricks Databricks $197.72 +$0.06 (0.03%)High $xxx.xx
SambaNova Systems SambaNova Systems $14.74 -$1.36 (8.45%)Medium $xxx.xx

Forge, your trusted partner for pre-IPO insights and Elektrofi data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Nov 20, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.